NO20071160L - Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel - Google Patents

Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel

Info

Publication number
NO20071160L
NO20071160L NO20071160A NO20071160A NO20071160L NO 20071160 L NO20071160 L NO 20071160L NO 20071160 A NO20071160 A NO 20071160A NO 20071160 A NO20071160 A NO 20071160A NO 20071160 L NO20071160 L NO 20071160L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
androgen deficiency
estrogen receptor
receptor modulator
selective estrogen
Prior art date
Application number
NO20071160A
Other languages
English (en)
Norwegian (no)
Inventor
Risto Lammintausta
Taru Blom
Janne Komi
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20041216A external-priority patent/FI20041216A0/fi
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of NO20071160L publication Critical patent/NO20071160L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20071160A 2004-09-03 2007-03-01 Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel NO20071160L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60690704P 2004-09-03 2004-09-03
FI20041216A FI20041216A0 (fi) 2004-09-21 2004-09-21 Menetelmä androgeenivajeen hoitoon tai estoon
PCT/FI2005/000333 WO2006024689A1 (fr) 2004-09-03 2005-07-20 Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniques

Publications (1)

Publication Number Publication Date
NO20071160L true NO20071160L (no) 2007-05-25

Family

ID=35999733

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071160A NO20071160L (no) 2004-09-03 2007-03-01 Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel

Country Status (10)

Country Link
EP (1) EP1786408A4 (fr)
JP (1) JP2008511615A (fr)
KR (1) KR20070059110A (fr)
AU (1) AU2005279178A1 (fr)
BR (1) BRPI0514701A (fr)
CA (1) CA2578852A1 (fr)
MX (1) MX2007002606A (fr)
NO (1) NO20071160L (fr)
RU (1) RU2007112114A (fr)
WO (1) WO2006024689A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5363344B2 (ja) 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
WO2008157335A2 (fr) * 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Procédés de traitement d'un dysfonctionnement érectile en utilisant du fispémifène
EP3205648A1 (fr) 2010-06-10 2017-08-16 Seragon Pharmaceuticals, Inc. Modulateur du récepteur oestrogénique et utilisation de ces derniers
WO2013090829A1 (fr) 2011-12-14 2013-06-20 Aragon Pharmaceuticals, Inc. Modulateurs des récepteurs des œstrogènes et ses utilisations
US9744177B2 (en) * 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
JP6697467B2 (ja) 2014-12-29 2020-05-20 オロン エス．ピー．エー． オスペミフェン及びフィスペミフェンを調製するためのプロセス
WO2023175010A1 (fr) * 2022-03-15 2023-09-21 Centre D'etude Des Cellules Souches (Cecs) Utilisation du bazedoxifene pour augmenter la survie musculaire

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
TW593256B (en) * 1999-11-16 2004-06-21 Hormos Medical Oy Ltd Triphenylalkene derivatives and their use as selective estrogen receptor modulators
CO5271697A1 (es) * 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP2003534375A (ja) * 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
EA200400744A1 (ru) * 2001-11-29 2005-02-24 Джи Ти Икс, ИНК. Предупреждение и лечение остеопороза, вызванного депривацией андрогенов

Also Published As

Publication number Publication date
MX2007002606A (es) 2007-05-15
JP2008511615A (ja) 2008-04-17
BRPI0514701A (pt) 2008-06-24
RU2007112114A (ru) 2008-10-10
KR20070059110A (ko) 2007-06-11
EP1786408A4 (fr) 2010-07-28
CA2578852A1 (fr) 2006-03-09
AU2005279178A1 (en) 2006-03-09
WO2006024689A1 (fr) 2006-03-09
EP1786408A1 (fr) 2007-05-23

Similar Documents

Publication Publication Date Title
NO20071160L (no) Anvendelse av en selektiv ostrogenreseptormodulator for fremstilling av et farmasoytisk preparat for anvendelse i en fremgangsmate for behandling eller forebygging av androgenmangel
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
MX2009001711A (es) Formulaciones de liberacion sostenida de topiramato.
ATE453642T1 (de) Substituierte phenylaminopyrimidine
WO2006015259A3 (fr) Composes et compositions comme modulateurs de recepteurs steroides
NO20092584L (no) Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse
DK1933833T3 (da) Terapi til behandling af overaktiv blære
MX2010003550A (es) Forma de dosificacion intraoral con multiples porciones con propiedades organolepticas.
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
EP2178869A4 (fr) Composés d'indole en tant qu'inhibiteurs de nécrose cellulaire
RS52199B (en) PHARMACEUTICAL COMPOSITIONS OF THE NEUROACTIVE STEROID AND THEIR USE
WO2007025005A3 (fr) Formulations de nalbuphine a liberation prolongee
WO2014170755A3 (fr) Formulations de colchicine à libération prolongée et procédés d'utilisation de ces dernières
NO20100301L (no) Forbedrete brimonidinsammensetninger for behandling av erytem
WO2006119389A3 (fr) Preparations de quinine
WO2007038506A3 (fr) Methode de traitement de la cachexie
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20080936L (no) Transdermale medikamentleveringsinnretninger inneholdende O-desmetylvenlafaksin (ODV) eller salter derav
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
NO20074332L (no) Fremgangsmate og preparat for behandling av sentralnervesystemforstyrrelser
DK1784173T3 (da) Farmaceutisk sammensætning til forebyggelse og behandling af metaboliske knoglesygdomme indeholdende alpha-arylmethoxyacrylatderivater
EA201171035A1 (ru) Композиции, включающие модуляторы pde4, и способ их применения для лечения, профилактики и сопровождения туберкулеза
WO2011047837A3 (fr) Cinacalcet granulé par fusion

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application